

# Olivier Glehen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3737385/olivier-glehen-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244  
papers

12,477  
citations

52  
h-index

107  
g-index

272  
ext. papers

14,904  
ext. citations

3.6  
avg, IF

6  
L-index

#	Paper	IF	Citations
244	Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.. <i>BMC Surgery</i> , <b>2022</b> , 22, 1	2.3	0
243	Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip). <i>Visceral Medicine</i> , <b>2022</b> , 38, 81-89	2.4	
242	Continuing Progress in the Interdisciplinary Management of Peritoneal Metastases. <i>Visceral Medicine</i> , <b>2022</b> , 38, 120-125	2.4	
241	An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.. <i>World Journal of Surgery</i> , <b>2022</b> , 1	3.3	
240	Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.. <i>Annals of Surgical Oncology</i> , <b>2022</b> , 1	3.1	3
239	Prehabilitation before major abdominal surgery: Evaluation of the impact of a perioperative clinical pathway, a pilot study.. <i>Scandinavian Journal of Surgery</i> , <b>2022</b> , 111, 14574969221083394	3.1	1
238	Primary and metastatic peritoneal surface malignancies.. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 91	51.1	4
237	Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. <i>European Journal of Surgical Oncology</i> , <b>2021</b> ,	3.6	2
236	Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). <i>Digestive and Liver Disease</i> , <b>2021</b> ,	3.3	1
235	Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 1	3.1	2
234	ASO Author Reflections: Bi-Directional Chemotherapy Using PIPAC Could Downstage Nonresectable Malignant Peritoneal Mesothelioma Patients to a Complete Resection. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 1	3.1	
233	The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. <i>JAMA Surgery</i> , <b>2021</b> , 156, e206363	5.4	22
232	Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 479, 765-772	5.1	3
231	The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 2888-2892	3.6	6
230	Limitations of the PRODIGE 7 trial - Authors' reply. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e179-e180	21.7	2
229	Greater-omentum lesion-score (GOLS) as a predictor of residual disease in different regions of the peritoneal cavity in patients undergoing interval cytoreductive surgery for advanced ovarian cancer and its potential clinical utility. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 2925-2932	3.6	0
228	Cytoreductive surgery in peritoneal carcinomatosis. <i>Journal of Visceral Surgery</i> , <b>2021</b> , 158, 258-264	1.9	0

227	Associations between the severity of medical and surgical complications and perception of surgeon empathy in esophageal and gastric cancer patients. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 7551-7561	3.9	0
226	ASO Author Reflections: Standardizing HIPEC Methodology and Regimens: a Prelude to the PSOGI Expert Consensus. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 9114-9115	3.1	0
225	Combined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 479, 927-936	5.1	1
224	HIPEC Methodology and Regimens: The Need for an Expert Consensus. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 9098-9113	3.1	1
223	Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 1420-1426	3.6	9
222	Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study. <i>BMJ Open</i> , <b>2021</b> , 11, e046819	3	0
221	Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 36-59	3.6	24
220	Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 123-127	3.6	17
219	Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 11-35	3.6	35
218	The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 4-10	3.6	5
217	Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative study. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 139-142	3.6	9
216	Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 128-133	3.6	14
215	Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: A multi-institutional cohort from PSOGI. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 172-180	3.6	5
214	Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI). <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 89-100	3.6	7
213	Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 181-187	3.6	2
212	ASO Author Reflections: Potential Therapeutic Implications and Prediction of Pathological Complete Response to Systemic Chemotherapy in Colorectal Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 3850-3851	3.1	4
211	Clinical and Radiologic Predictors of a Pathologic Complete Response to Neoadjuvant Chemotherapy (NACT) in Patients Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases: Results of a Prospective Multi-center Study. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 3840-3849	3.1	6
210	Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI). <i>Oncology</i> , <b>2021</b> , 99, 41-48	3.6	1

209	Multicystic peritoneal mesothelioma treated with cytoreductive surgery followed or not by hyperthermic intraperitoneal chemotherapy: results from a large multicentric cohort. <i>International Journal of Hyperthermia</i> , <b>2021</b> , 38, 805-814	3.7	1
208	Prehabilitation of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 60-64	3.6	9
207	Indication of CRS and HIPEC in Gastric Cancer-Related Peritoneal Metastasis <b>2021</b> , 189-201		
206	Chirurgie de cytoréduction dans la carcinose péritonéale. <i>Journal De Chirurgie Viscérale</i> , <b>2021</b> , 158, 282-282	0	
205	Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 256-266	21.7	122
204	Half of Postoperative Deaths After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Could be Preventable: A French Root Cause Analysis on 5562 Patients. <i>Annals of Surgery</i> , <b>2021</b> , 274, 797-804	7.8	0
203	Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). <i>British Journal of Surgery</i> , <b>2021</b> , 108, 1225-1235	5.3	0
202	Implications of Pathologic Findings in Cytoreductive Surgery Specimens on Treatment of Colorectal Peritoneal Metastases: Results of a Prospective Multicentric Study. <i>Diseases of the Colon and Rectum</i> , <b>2021</b> , 64, 534-544	3.1	1
201	Expanding Uses of HIPEC for Locally Advanced Colorectal Cancer: A European Perspective. <i>Clinics in Colon and Rectal Surgery</i> , <b>2020</b> , 33, 253-257	2.3	0
200	Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups. <i>Journal of Visceral Surgery</i> , <b>2020</b> , 157, S25-S31	1.9	8
199	ASO Author Reflections: Tailoring the Extent of Peritoneal Resection for Peritoneal Metastases According to the Primary Tumor Site. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 1471-1472	3.1	1
198	Surgical management of gastric adenocarcinoma. Official expert recommendations delivered under the aegis of the French Association of Surgery (AFC). <i>Journal of Visceral Surgery</i> , <b>2020</b> , 157, 117-126	1.9	2
197	Extent and distribution of peritoneal disease in patients undergoing cytoreductive surgery for first platinum sensitive recurrence in ovarian cancer and its potential therapeutic implications. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 2276-2282	3.6	0
196	Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. <i>Histopathology</i> , <b>2020</b> , 77, 548-559	7.3	16
195	The Pathologic Peritoneal Cancer Index (PCI) Strongly Differs From the Surgical PCI in Peritoneal Metastases Arising From Various Primary Tumors. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 2985-2996	3.1	19
194	Extent of Peritoneal Resection for Peritoneal Metastases: Looking Beyond a Complete Cytoreduction. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 1458-1470	3.1	9
193	Extent of Peritoneal Resection for Peritoneal Metastases: Inferences from Pathophysiology <b>2020</b> , 27-45		1
192	Therapeutic Rationale and Data Set for Reporting Cytoreductive Surgery Specimens <b>2020</b> , 47-66		

191	Colorectal Peritoneal Metastases: Correlating Histopathological Findings and Disease Biology <b>2020</b> , 67-87		
190	Prise en charge chirurgicale de l'adénocarcinome gastrique. Recommandations formalisées d'experts sous l'égide de l'Association française de chirurgie (AFC). <i>Journal De Chirurgie Viscérale</i> , <b>2020</b> , 157, 121-131	0	1
189	État des lieux et perspectives dans la prise en charge des métastases péritonéales d'origine colorectale. <i>Colon and Rectum</i> , <b>2020</b> , 14, 214-225	0	
188	Epithelial Serous Ovarian Cancer: Patterns of Peritoneal Dissemination and their Clinical Implications <b>2020</b> , 89-116		
187	Biomarkers in the Management of Peritoneal Metastases <b>2020</b> , 251-279		1
186	PIPAC versus HIPEC: cisplatin spatial distribution and diffusion in a swine model. <i>International Journal of Hyperthermia</i> , <b>2020</b> , 37, 144-150	3.7	5
185	Target region resection in patients undergoing cytoreductive surgery for peritoneal metastases-is it necessary in absence of visible disease?. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 582-589	3.6	10
184	Ovarian and peritoneal psammocarcinoma: Results of a multicenter study on 25 patients. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 862-867	3.6	1
183	The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. <i>EBioMedicine</i> , <b>2020</b> , 51, 102574	8.8	6
182	Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. <i>Cancer Letters</i> , <b>2020</b> , 472, 29-39	9.9	7
181	Centralization and Oncologic Training Reduce Postoperative Morbidity and Failure-to-rescue Rates After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Study on a 10-year National French Practice. <i>Annals of Surgery</i> , <b>2020</b> , 272, 847-854	7.8	10
180	Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes region. <i>European Journal of Cancer Care</i> , <b>2020</b> , 29, e13313	2.4	
179	A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. <i>European Journal of Cancer</i> , <b>2020</b> , 140, 37-44	7.5	21
178	Patient Selection for Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Cancer: Consensus on Decision Making Among International Experts. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 277-284	3.8	6
177	Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. <i>Lancet Oncology</i> , <b>2020</b> , 21, 1147-1154	21.7	54
176	Sodium thiosulfate protects from renal impairment following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin. <i>International Journal of Hyperthermia</i> , <b>2020</b> , 37, 897-902	3.7	10
175	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPERitoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS <sup>®</sup> ) Society Recommendations - Part II: Postoperative management and special considerations. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 2311-2323	3.6	28
174	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPERitoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS <sup>®</sup> ) Society Recommendations - Part I: Preoperative and intraoperative management. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 2292-2310	3.6	33

173	Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6
172	Prospective correlation of the radiological, surgical and pathological findings in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: implications for the preoperative estimation of the peritoneal cancer index. <i>Colorectal Disease</i> , <b>2020</b> , 22, 2123-2132	2.1	5
171	Risk of Omental Metastases in Patients Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases. <i>Diseases of the Colon and Rectum</i> , <b>2020</b> , 63, 1251-1256	3.1	4
170	Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>BJS Open</i> , <b>2019</b> , 3, 195-202	3.9	20
169	Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2028-2040	2.2	114
168	Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study. <i>Cancer Epidemiology</i> , <b>2019</b> , 60, 106-111	2.8	12
167	A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2019</b> , 33, 854-860	5.2	23
166	An update of peritonectomy procedures used in cytoreductive surgery for peritoneal malignancy. <i>International Journal of Hyperthermia</i> , <b>2019</b> , 36, 744-752	3.7	7
165	Assessment of the aerosol distribution pattern of a single-port device for intraperitoneal administration of therapeutic substances. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2019</b> , 33, 3503-3510	5.2	2
164	Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential-a prospective multi-centric study. <i>European Journal of Surgical Oncology</i> , <b>2019</b> , 45, 2398-2404	3.6	19
163	Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. <i>Lancet Oncology</i> , <b>2019</b> , 20, e368-e377	21.7	124
162	La chirurgie de cytoréduction péritonéale : de l' incurable vers le curable. <i>Bulletin De L'Académie Nationale De Médecine</i> , <b>2019</b> , 203, 587-595	0.1	
161	Une omentectomie totale par laparotomie est indispensable pour toute chirurgie potentiellement curative d'une carcinose péritonéale d'origine colorectale. <i>Journal De Chirurgie Viscérale</i> , <b>2019</b> , 156, e17	0	3
160	The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. <i>Surgery</i> , <b>2019</b> , 165, 476-484	3.6	8
159	Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry. <i>European Journal of Surgical Oncology</i> , <b>2019</b> , 45, 371-375	3.6	11
158	Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 852-860	3.1	13
157	Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 83, 425-430	3.5	16
156	Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience. <i>Journal of Surgical Oncology</i> , <b>2019</b> , 119, 336-346	2.8	16

155	Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. <i>International Journal of Surgery</i> , <b>2018</b> , 51, 120-127	7.5	61
154	Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 1942-1948	3.6	61
153	Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 799-804	3.6	3
152	Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE). <i>British Journal of Surgery</i> , <b>2018</b> , 105, 663-667	5.3	44
151	Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 1668-1675	3.1	14
150	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. <i>British Journal of Surgery</i> , <b>2018</b> , 105, 668-676	5.3	30
149	Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread: A French nationwide study over 14 years. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e26934	3	11
148	Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 667-673	3.1	15
147	What the radiologist should know about postoperative MDCT evaluation of a patient treated with cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy. <i>Clinical Radiology</i> , <b>2018</b> , 73, 517-525	2.9	1
146	Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 179-187	3.1	17
145	Ninety-day post-operative morbidity and mortality using the National Cancer Institute's common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>International Journal of Hyperthermia</i> , <b>2018</b> , 34, 532-537	3.7	27
144	Preoperative nutritional risk assessment in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal carcinomatosis. <i>International Journal of Hyperthermia</i> , <b>2018</b> , 34, 589-594	3.7	10
143	Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Procedure for Non-resectable Peritoneal Carcinomatosis (with Video). <i>Journal of Gastrointestinal Surgery</i> , <b>2018</b> , 22, 374-375	3.3	14
142	The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 1942-1948	3.6	71
141	Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 1818-1823	3.6	7
140	Complex Biliary Leaks: Effectiveness of Percutaneous Radiological Treatment Compared to Simple Leaks in 101 Patients. <i>CardioVascular and Interventional Radiology</i> , <b>2018</b> , 41, 1566-1572	2.7	8
139	Surgical Management of Recurrent Epithelial Ovarian Cancer <b>2018</b> , 253-280		1
138	Pseudomyxoma Peritonei Arising from Epithelial Appendiceal Tumours <b>2018</b> , 317-346		2

137	Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGL and BIG RENAPE groups. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 1378-1383	3.6	12
136	A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, LBA3503-LBA3503	2.2	205
135	Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 1094-1100	3.1	10
134	Prediction of Resectability in Pseudomyxoma Peritonei with a New CT Score. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 694-701	3.1	21
133	Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design. <i>Pleura and Peritoneum</i> , <b>2018</b> , 3, 20180120	2	20
132	No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis. <i>Anticancer Research</i> , <b>2018</b> , 38, 6869-6875	2.3	6
131	Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>International Journal of Hyperthermia</i> , <b>2018</b> , 35, 652-657	3.7	13
130	Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin. <i>Annals of Surgery</i> , <b>2018</b> , 268, 845-853	7.8	52
129	Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 1786-1792	3.6	17
128	A Perioperative Clinical Pathway Can Dramatically Reduce Failure-to-rescue Rates After Cytoreductive Surgery for Peritoneal Carcinomatosis: A Retrospective Study of 666 Consecutive Cytoreductions. <i>Annals of Surgery</i> , <b>2017</b> , 265, 806-813	7.8	30
127	Reconstruction urétrale en cas d'extirpation de l'uretère pelvien suivie de CHIP: la réimplantation sur vessie prothétique semble plus sûre que l'anastomose urétrale termino-terminale. <i>Journal De Chirurgie Viscérale</i> , <b>2017</b> , 154, 236-240	0	
126	The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma. <i>Nuclear Medicine Communications</i> , <b>2017</b> , 38, 312-318	1.6	16
125	Registries on peritoneal surface malignancies throughout the world, their use and their options. <i>International Journal of Hyperthermia</i> , <b>2017</b> , 33, 528-533	3.7	12
124	Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study. <i>European Journal of Surgical Oncology</i> , <b>2017</b> , 43, 1915-1923	3.6	17
123	Evaluation of the peritoneal carcinomatosis index with CT and MRI. <i>British Journal of Surgery</i> , <b>2017</b> , 104, 1244-1249	5.3	63
122	Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGL). <i>International Journal of Hyperthermia</i> , <b>2017</b> , 33, 520-527	3.7	44
121	Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymoma. <i>Lung Cancer</i> , <b>2017</b> , 108, 1-6	5.9	24
120	BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 724-733	8.9	45



119	Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. <i>European Journal of Surgical Oncology</i> , <b>2017</b> , 43, 2178-2183	3.6	66
118	Total Mesenteric Peritonectomy for Peritoneal Metastases (with video). <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 3988-3989	3.1	7
117	A prototype single-port device for pressurized intraperitoneal aerosol chemotherapy. Technical feasibility and local drug distribution. <i>Acta Cirurgica Brasileira</i> , <b>2017</b> , 32, 1056-1063	1.6	6
116	Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery?. <i>PLoS ONE</i> , <b>2017</b> , 12, e0171639 <sup>3.7</sup>	3.7	39
115	Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>European Journal of Surgical Oncology</i> , <b>2017</b> , 43, 2170-2177	3.6	15
114	Reconstruction after ureteral resection during HIPEC surgery: Re-implantation with uretero-neocystostomy seems safer than end-to-end anastomosis. <i>Journal of Visceral Surgery</i> , <b>2017</b> , 154, 227-230	1.9	7
113	The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry. <i>Orphanet Journal of Rare Diseases</i> , <b>2017</b> , 12, 37	4.2	23
112	Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. <i>European Journal of Cancer</i> , <b>2016</b> , 65, 69-79	7.5	52
111	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis in the Elderly: A Case-Controlled, Multicenter Study. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 737-745	3.1	18
110	Intraperitoneal-Free Cancer Cells Represent a Major Prognostic Factor in Colorectal Peritoneal Carcinomatosis. <i>Diseases of the Colon and Rectum</i> , <b>2016</b> , 59, 615-22	3.1	12
109	Laparoscopic Colonic Resection Without Urinary Drainage: Is It "Feasible"?. <i>Journal of Gastrointestinal Surgery</i> , <b>2016</b> , 20, 1388-92	3.3	11
108	Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 1261-7	3.6	24
107	Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array. <i>Human Pathology</i> , <b>2016</b> , 55, 72-82	3.7	32
106	Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. <i>Gynecologic Oncology</i> , <b>2016</b> , 142, 237-42	4.9	33
105	Pathologic Response, When Increased by Longer Interval, Is a Marker but Not the Cause of Good Prognosis in Rectal Cancer: 17-year Follow-up of the Lyon R90-01 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 94, 544-53	4	42
104	Resectability of Peritoneal Carcinomatosis: Learnings from a Prospective Cohort of 533 Consecutive Patients Selected for Cytoreductive Surgery. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 1261-70 <sup>3.1</sup>	3.1	20
103	Preoperative CT and MRI prediction of non-resectability in patients treated for pseudomyxoma peritonei from mucinous appendiceal neoplasms. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 558-66 <sup>3.6</sup>	3.6	38
102	Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 1971-9	3.1	97

101	Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score. <i>Surgical Oncology</i> , <b>2016</b> , 25, 6-15	2.5	26
100	Is signet-ring cell carcinoma a specific entity among gastric cancers?. <i>Gastric Cancer</i> , <b>2016</b> , 19, 1027-1040	7.6	38
99	Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Isolated Peritoneal Carcinomatosis of Colon Cancer: A Multicenter Study. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 863-9	3.1	34
98	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 1114-30	5.6	49
97	Is Extended Lymphadenectomy Needed for Elderly Patients With Gastric Adenocarcinoma?. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 2391-7	3.1	6
96	Digital Glissonectomy: A Safe Perihepatic Peritonectomy. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 3978-3985	12	12
95	Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review. <i>Pleura and Peritoneum</i> , <b>2016</b> , 1, 67-77	7	7
94	A new internet tool to report peritoneal malignancy extent. PeRitOneal Malignancy Stage Evaluation (PROMISE) application. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 877-82	3.6	34
93	The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer. <i>Indian Journal of Surgical Oncology</i> , <b>2016</b> , 7, 198-207	0.7	10
92	FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1630-7	8.8	7
91	The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review. <i>Indian Journal of Surgical Oncology</i> , <b>2016</b> , 7, 188-97	0.7	38
90	Cytoreductive Surgery and Peritonectomy Procedures. <i>Indian Journal of Surgical Oncology</i> , <b>2016</b> , 7, 139-51	17	34
89	Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 2315-22	3.1	32
88	Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 1980-5	3.1	24
87	No impact on long-term survival of prolonged ICU stay and re-admission for patients undergoing cytoreductive surgery with HIPEC. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 855-60	3.6	6
86	A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 1123-31	3.6	67
85	Impact des mutations de RAS pour les cancers colorectaux stade IV : importance du site métastatique après résection curative. <i>Journal De Chirurgie Viscérale</i> , <b>2016</b> , 153, A13	0	
84	What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures. <i>Journal of Surgical Oncology</i> , <b>2016</b> , 113, 796-803	2.8	83

83	Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey. <i>European Journal of Surgical Oncology</i> , <b>2015</b> , 41, 1361-7	3.6	23
82	Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , <b>2015</b> , 41, 911-9	3.6	63
81	An explosive side effect of albuterol nebulizers. <i>Surgery</i> , <b>2015</b> , 158, 1444-5	3.6	
80	Intraperitoneal Vascular Endothelial Growth Factor: A Prognostic Factor and the Potential for Intraperitoneal Bevacizumab Use in Peritoneal Surface Malignancies. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22 Suppl 3, S880-7	3.1	6
79	Prédiction des complications précoces graves après chirurgie de cytoréduction pour carcinose péritonéale : le score TAFL. <i>Anesthésie &amp; Réanimation</i> , <b>2015</b> , 1, A329-A330	0.1	
78	Glisson capsulectomy for extensive superficial liver involvement in peritoneal carcinomatosis (with video). <i>Journal of Visceral Surgery</i> , <b>2015</b> , 152, 332-3	1.9	8
77	Chirurgie de cytoréduction et carcinoses péritonéales. <i>Colon and Rectum</i> , <b>2015</b> , 9, 103-110	0	
76	Controverse. <i>Colon and Rectum</i> , <b>2015</b> , 9, 230-234	0	
75	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for First Relapse of Ovarian Cancer. <i>Anticancer Research</i> , <b>2015</b> , 35, 4997-5005	2.3	22
74	Signet ring cell adenocarcinomas: different clinical-pathological characteristics of oesophageal and gastric locations. <i>European Journal of Surgical Oncology</i> , <b>2014</b> , 40, 1746-55	3.6	20
73	La chimiohyperthermie intrapéritonéale (CHIP) dans les cancers ovariens. <i>Journal De Chirurgie Viscérale</i> , <b>2014</b> , 151, 358-365	0	1
72	Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. <i>Journal of Visceral Surgery</i> , <b>2014</b> , 151, 347-53	1.9	39
71	The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. <i>Journal of Surgical Oncology</i> , <b>2014</b> , 110, 779-85	2.8	108
70	Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 2608-14	3.1	85
69	Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. <i>BMC Cancer</i> , <b>2014</b> , 14, 148	4.8	35
68	Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: the first step before intraperitoneal anti-vascular endothelial growth factor treatment?. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 722-30	7.5	9
67	Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. <i>European Journal of Surgical Oncology</i> , <b>2014</b> , 40, 12-26	3.6	152
66	Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. <i>European Journal of Surgical Oncology</i> , <b>2014</b> , 40, 529-535	3.6	50

65	The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 4195-201	3.1	114
64	American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. <i>Journal of Surgical Oncology</i> , <b>2014</b> , 110, 777-8	2.8	42
63	GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. <i>BMC Cancer</i> , <b>2014</b> , 14, 183	4.8	118
62	Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies. <i>European Journal of Surgical Oncology</i> , <b>2014</b> , 40, 957-62	3.6	43
61	Response to: "hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer should be proposed in eight time points". <i>European Journal of Surgical Oncology</i> , <b>2014</b> , 40, 1030-1	3.6	
60	Intra-operative peritoneal lavage for colorectal cancer. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 1935-9	3.0	9
59	Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis. <i>Cell Stress and Chaperones</i> , <b>2013</b> , 18, 623-30	4	6
58	Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 3892-8	3.1	16
57	Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal Malignancies). <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 2655-62	3.1	9
56	Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. <i>European Journal of Surgical Oncology</i> , <b>2013</b> , 39, 1435-43	3.6	189
55	Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: results of EVOCAPE 2 multicentre prospective study. <i>European Journal of Surgical Oncology</i> , <b>2013</b> , 39, 707-14	3.6	37
54	Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients. <i>European Journal of Surgical Oncology</i> , <b>2013</b> , 39, 742-7	3.6	23
53	Quality indicators in ovarian cancer surgery: report from the French Society of Gynecologic Oncology (Societe Francaise d'Oncologie Gynecologique, SFOG). <i>Annals of Oncology</i> , <b>2013</b> , 24, 2732-9	10.3	22
52	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 4052-8	3.1	77
51	Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics. <i>Cancer Investigation</i> , <b>2012</b> , 30, 209-24	2.1	68
50	Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model. <i>Clinical and Translational Oncology</i> , <b>2012</b> , 14, 931-6	3.6	10
49	Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. <i>Journal of Surgical Oncology</i> , <b>2012</b> , 106, 197-203	2.8	51
48	Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2449-56	2.2	680

47	Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. <i>Annals of Surgery</i> , <b>2012</b> , 256, 125-9	7.8	69
46	Hyperthermic intraperitoneal chemotherapy in advanced gastric cancer: the end of skepticism?. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 1524-6	3.1	9
45	Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 2599-603	3.1	15
44	Peritoneal carcinomatosis from appendiceal cancer: early adequate therapeutic management for long-term survival. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 1522-3	3.1	1
43	A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. <i>Cancer</i> , <b>2011</b> , 117, 1855-63	6.4	105
42	Population pharmacokinetics and pharmacodynamics of cisplatin during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure. <i>Journal of Clinical Pharmacology</i> , <b>2011</b> , 51, 9-18	2.9	30
41	The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. <i>Annals of Surgery</i> , <b>2011</b> , 254, 684-93; discussion 693	7.8	136
40	Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. <i>British Journal of Surgery</i> , <b>2011</b> , 98, 60-4	5.3	57
39	Selection of patients and staging of peritoneal surface malignancies. <i>World Journal of Gastrointestinal Oncology</i> , <b>2010</b> , 2, 31-5	3.4	70
38	Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 63-8	2.2	713
37	Pseudomyxoma peritonei: role of 18F-FDG PET in preoperative evaluation of pathological grade and potential for complete cytoreduction. <i>European Journal of Surgical Oncology</i> , <b>2010</b> , 36, 315-23	3.6	33
36	Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. <i>European Journal of Surgical Oncology</i> , <b>2010</b> , 36, 456-62	3.6	177
35	A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. <i>Annals of Surgery</i> , <b>2010</b> , 251, 896-901	7.8	120
34	Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, 809-14	3.5	19
33	Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 2370-7	3.1	330
32	Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. <i>Cancer</i> , <b>2010</b> , 116, 5608-18	6.4	385
31	Mesothelioma peritoneal <b>2010</b> , 533-536		
30	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6237-42	2.2	498

29	Appraisal of peritoneal cavity's capacity in order to assess the pharmacology of liquid chemotherapy solution in hyperthermic intraperitoneal chemotherapy. <i>Surgical and Radiologic Anatomy</i> , <b>2009</b> , 31, 573-8	1.4	10
28	Lymphadenectomy for colon cancer: is there a consensus?. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 1454-53	3.1	3
27	Management of peritoneal carcinomatosis from colorectal cancer: current state of practice. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2009</b> , 15, 243-8	2.2	27
26	Pathologie tumorale du mésentère et du péritoine. <i>EMC - Radiologie Et Imagerie Médicale - Abdominale - Digestive</i> , <b>2008</b> , 3, 1-9		
25	Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. <i>Journal of Surgical Oncology</i> , <b>2008</b> , 98, 242-6	2.8	104
24	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. <i>Annals of Surgical Oncology</i> , <b>2007</b> , 14, 128-33	3.1	337
23	Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. <i>World Journal of Surgery</i> , <b>2007</b> , 31, 1813-1820	3.3	121
22	Pathologie tumorale du mésentère et du péritoine. <i>EMC - Gastro-entérologie</i> , <b>2007</b> , 2, 1-9		
21	Quantitative prognostic indices in peritoneal carcinomatosis. <i>European Journal of Surgical Oncology</i> , <b>2006</b> , 32, 597-601	3.6	59
20	MRI evaluation of bulky tumor masses in the mesentery and bladder involvement in peritoneal carcinomatosis. <i>European Journal of Surgical Oncology</i> , <b>2006</b> , 32, 1212-6	3.6	11
19	Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 405-12	3.1	106
18	In vitro thermochemotherapy of colon cancer cell lines with irinotecan alone and combined with mitomycin C. <i>Hepato-Gastroenterology</i> , <b>2006</b> , 53, 693-7		7
17	Intraperitoneal treatment with dimethylthioampl (DIMATE) combined with surgical debulking is effective for experimental peritoneal carcinomatosis in a rat model. <i>Journal of Gastrointestinal Surgery</i> , <b>2005</b> , 9, 769-74	3.3	11
16	Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. <i>Diseases of the Colon and Rectum</i> , <b>2005</b> , 48, 1372-9	3.1	91
15	Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3284-92	2.2	927
14	Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2004</b> , 54, 79-84	3.5	24
13	Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. <i>British Journal of Surgery</i> , <b>2004</b> , 91, 747-54	5.3	162
12	Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. <i>Lancet Oncology, The</i> , <b>2004</b> , 5, 219-28	21.7	291

11	Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. <i>Annals of Surgery</i> , <b>2004</b> , 240, 278-85	7.8	90
10	Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. <i>Archives of Surgery</i> , <b>2004</b> , 139, 20-6		171
9	A review of peritoneal mesothelioma at the Washington Cancer Institute. <i>Surgical Oncology Clinics of North America</i> , <b>2003</b> , 12, 605-21, xi	2.7	204
8	Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. <i>Surgical Oncology Clinics of North America</i> , <b>2003</b> , 12, 649-71	2.7	76
7	Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 799-806	2.2	206
6	Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. <i>Annals of Surgical Oncology</i> , <b>2003</b> , 10, 863-9	3.1	271
5	Spontaneous dissection of the celiac artery. <i>Annals of Vascular Surgery</i> , <b>2001</b> , 15, 687-92	1.7	91
4	Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. <i>Cancer</i> , <b>2000</b> , 88, 358-63	6.4	873
3	Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. <i>Cancer</i> , <b>2000</b> , 88, 2512-9	6.4	140
2	Intraperitoneal chemo-hyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis. <i>Anticancer Research</i> , <b>1999</b> , 19, 1375-82	2.3	48
1	Hyperthermic Intraperitoneal Chemotherapy in the Treatment Armamentarium of Epithelial Ovarian Cancer: Time to End the Dichotomy. <i>Visceral Medicine</i> , 1-11	2.4	